Geographic Atrophy Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Geographic Atrophy remains an active clinical development field. The strongest programs are pairing biologically differentiated interventions with patient-centered outcomes, less burdensome delivery and longer evidence windows. The PatSnap evidence set used here contains 77 matched trial records and 112 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07668804 | TOO-1007 | Phase 1/2; Recruiting | Theratocular Biotek Co., Ltd. | Australia | Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (Up to 6 months treatment duration) | 2027-08-31 |
| JPRN-jRCT1050260065 | Intervention not normalized | Not Applicable; 募集中 | Sponsor not listed | Japan | Descriptive statistics of ophthalmological clinical findings and patient characteristics, and comparison of QOL scores; 眼科的臨床所見・患者背景の記述統計、QOLスコアの比較 | 2031-03-31 |
| NCT07606365 | Intervention not normalized | Phase 2; Not yet recruiting | Sitala Bio Ltd. | Argentina, Czechia, United States, Poland, United Kingdom +2 more | Reduction of rate of total EZ area loss (From baseline to Week 52) | 2028-07-01 |
| NCT07602127 | Intervention not normalized | Early Phase 1; Not yet recruiting | Zhongmou Therapeutics (Wuhan) Co., Ltd. | Geography not listed | Incidence of treatment-emergent adverse events,adverse events, serious adverse events and dose-limiting toxicities (baseline to Week 52) | 2028-12-30 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (GATHER2) (Phase 3): the indexed record reports Number of Participants With Adverse Events (AEs) = 129 Participants; -; -.
- A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration (Phase 2/3): the indexed record reports Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF)(Least Squares Mean) = 1.87 mm2/year (Standard Error, 0.116); -; Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF)(Least Squares Mean) = 1.62 mm2/year (Standard Error, 0.081).
- Extension of Protocol 002, Carbidopa-levodopa in Neovascular Extension of Protocol 002, Carbidopa-levodopa in Neovascular AMD (Phase 2): the indexed record reports Change in Best Corrected Visual Acuity by ETDRS Visual Scale Testing(Mean) = 2.7 Change in letters (BCVA) (Standard Error, 1.8); -; -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including TOO-1007 (Phase 1/2). Company & Deal Intelligence records identify sponsor context for Theratocular Biotek Co., Ltd., Sitala Bio Ltd., Zhongmou Therapeutics (Wuhan) Co., Ltd.. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Endpoints that capture daily function and treatment burden alongside biological change.
- Long-duration comparisons against current procedural or pharmacologic standards.
- Evidence across diverse ages, disease stages and reproductive contexts.
- Delivery approaches that improve persistence without sacrificing safety.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Geographic Atrophy has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
